SKYE vs JTAI Comparison

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Jet AI Inc is principally involved in the sale of fractional and whole interests in aircraft, the sale of jet cards, which enable holders to use certain of the company's and other's aircraft at agreed-upon rates, the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third-party carriers as well as via the company's leased and managed aircraft, direct chartering of its HondaJet Elite aircraft by Cirrus Aviation Services, aircraft brokerage and monthly management and hourly operation of customer aircraft. It also offers the SaaS software to aircraft owners and operators generally: Reroute AI; and DynoFlight. The company operates in a single operating and reportable segment which is private aviation services.